Latest Articles
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Phase 2a Endometriosis Study of Teverelix - quiverquant.com
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Phase 2a Endometriosis Study of Teverelix quiverquant.com
Published: July 31, 2026, 11:40 a.m.
Medicus Pharma receives UAE approval for endometriosis study By Investing.com - Investing.com Canada
Medicus Pharma receives UAE approval for endometriosis study By Investing.com Investing.com Canada
Published: July 31, 2026, 11:39 a.m.
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com - Investing.com Australia
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com Investing.com Australia
Published: July 31, 2026, 11:35 a.m.
EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi - Benzinga
EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi Benzinga
Published: July 31, 2026, 11:15 a.m.
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer - Endpoints News
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer Endpoints News
Published: July 31, 2026, 10:42 a.m.
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix - Proactive financial news
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix Proactive financial news
Published: July 31, 2026, 9:24 a.m.
Beloved resident black bear dies at Maine Wildlife Park - newscentermaine.com
Beloved resident black bear dies at Maine Wildlife Park newscentermaine.com
Published: July 31, 2026, 12:02 a.m.
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer - Seeking Alpha
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer Seeking Alpha
Published: July 30, 2026, 11:38 p.m.
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study - FirstWord Pharma
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study FirstWord Pharma
Published: July 30, 2026, 9:59 p.m.
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint - TipRanks
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint TipRanks
Published: July 30, 2026, 9:16 p.m.
Link copied to clipboard!